Popular Searches
Diphenyleneiodonium chlorideEpacadostatGilteritinibDinaciclibRo-3306
TargetMol | Star Product
Wikimole
TargetMol | New Product
New Product
TargetMol | Compound Library
Compound Library
Contact Us
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
TOPRelated productsBioactivityChemical infoStorage&SolubilityCalculator

Delcasertib

🥰Excellent
Catalog No. T11740Cas No. 949100-39-4
Alias KAI-9803, BMS-875944

Delcasertib (KAI-9803) is a potent and selective inhibitor of δ-protein kinase C (δPKC).

Delcasertib
Other Forms of Delcasertib:

Delcasertib

🥰Excellent
Purity: 99.96%
Catalog No. T11740Alias KAI-9803, BMS-875944Cas No. 949100-39-4
Delcasertib (KAI-9803) is a potent and selective inhibitor of δ-protein kinase C (δPKC).
Pack SizePriceAvailabilityQuantity
1 mg$213In Stock
5 mg$538In Stock
10 mg$778In Stock
25 mg$1,180In Stock
50 mg$1,620In Stock
100 mg$2,180In Stock
1 mL x 10 mM (in DMSO)$1,780In Stock
Bulk & Custom
Add to Cart
Questions
View More

Related Compound Libraries of "Delcasertib"

Select Batch
Purity:99.96%
Contact us for more batch information
Resource Download
COA LCMS
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Product Introduction

Bioactivity
Description
Delcasertib (KAI-9803) is a potent and selective inhibitor of δ-protein kinase C (δPKC).
In vitro
Delcasertib is composed of a selective δ-protein kinase C (δPKC) inhibitor peptide derived from the δV1-1 portion of δPKC (termed 'cargo peptide”), conjugated reversibly to the cell-penetrating peptide 11-amino acid, arginine-rich sequence of the HIV type 1 transactivator protein (TAT47–57; termed 'carrier peptide”) via a disulfide bond.
In vivo
KAI-9803 ameliorates pathological conditions in acute myocardial infarction and reduce pain via specific modulation of membrane-translocation of PKC delta or epsilon. Delcasertib has an acceptable safety and tolerability profile when delivered via intracoronary injection during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.Delcasertib administration at the end of ischemia has been found to reduce cardiac damage caused by ischemia-reperfusion in a rat model of acute myocardial infarction. 14C-KAI-9803 is rapidly delivered to many tissues, including the heart (1.21 μg eq/g tissue), while being quickly cleared from the systemic circulation. The distribution of Delcasertib to tissues such as the liver, kidney, and heart is facilitated by the reversible conjugation to TAT47–57.
AliasKAI-9803, BMS-875944
Chemical Properties
Molecular Weight2880.28
FormulaC120H199N45O34S2
Cas No.949100-39-4
Smiles[C@H](CC1=CC=C(O)C=C1)(C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N[C@@H](CC(C)C)C(O)=O)=O)CO)=O)=O)CC(C)C)=O)CCC(O)=O)=O)NC([C@@H](NC([C@@H](NC([C@H](CC2=CC=CC=C2)NC([C@@H](NC([C@H](CSSC[C@@H](C(N[C@@H](CC3=CC=C(O)C=C3)C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CCCNC(=N)N)C(O)=O)=O)CCCNC(=N)N)=O)CCCNC(=N)N)=O)CCC(N)=O)=O)CCCNC(=N)N)=O)CCCNC(=N)N)=O)CCCCN)=O)CCCCN)=O)CCCNC(=N)N)=O)=O)=O)N)N)=O)CO)=O)=O)CC(N)=O)=O)CO)=O
Relative Density.1.54 g/cm3 (Predicted)
Storage & Solubility Information
Storagekeep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
Solubility Information
DMSO: 99 mg/mL (34.37 mM)
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM0.3472 mL1.7359 mL3.4719 mL17.3594 mL
5 mM0.0694 mL0.3472 mL0.6944 mL3.4719 mL
10 mM0.0347 mL0.1736 mL0.3472 mL1.7359 mL
20 mM0.0174 mL0.0868 mL0.1736 mL0.8680 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

δPKCProtein kinase CPKCδPKCKAI9803KAI 9803InhibitorinhibitDelcasertibBMS875944BMS 875944
Related Tags: buy Delcasertib | purchase Delcasertib | Delcasertib cost | order Delcasertib | Delcasertib chemical structure | Delcasertib in vivo | Delcasertib in vitro | Delcasertib formula | Delcasertib molecular weight
TargetMol | Logo

Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.